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Summary The therapeutic antitumour activity and host toxicity of cis-platin (CDDP), which was admini-
stered with selenium (sodium selenite) was studied on the growth of a human yolk sac tumour grown in nude
mice. Treatment consisted of CDDP single agent chemotherapy (3 weeks) or preliminary PVB combination
chemotherapy (CDDP+vinblastine +bleomycin, 2 weeks). Selenium was co-administered from day 1 to 5 with
each therapeutic regimen. The administration of CDDP alone caused significant reduction in tumour burden
but at higher doses there was significant host toxicity. The co-administration of selenium together with CDDP
(CDDP: selenium, molar ratio=3.5:1) did not affect the anti-tumour activity of CDDP but it did cause a
decrease of parameters of host toxicity including lethality, increasing the 50% lethal dose (LD50) from
9.3mgkg-1 to 17.5mgkg-1. The parameters of host toxicity which were altered by selenium co-admini-
stration were nephrotoxicity, myeloid suppression and weight loss. Our study suggested that selenium co-
administration allows higher doses of CDDP with reduction of apparent toxicity, resulting in a higher
therapeutic index and possibly indicating a potential increase in the utilization of CDDP in clinical cancer
chemotherapy.
Cis-platin (cis-diamminedichloroplatinum(II), CDDP, is an
effective agent in treatment of human cancers including germ
cell tumours (Merrin, 1979; Prestayko et al., 1979; Ozols et
al., 1984; Wiltshaw et al., 1985). Ovarian yolk sac tumour is
a rare but highly malignant germ cell tumour that occurs
primarily in children and young adults (Kurman & Norris,
1976; Scully, 1979). Recently, progress in combination
chemotherapy using CDDP (CDDP+vinblastine +bleomycin,
PVB regimen) has markedly improved patient survival (Ein-
horn & Donohue, 1977; Jacobs et al., 1982; Williams et al.,
1987). These agents cause considerable adverse side effects
which include renal damage, myeloid suppression and severe
nausea and vomiting. Nephrotoxicity has been cited as a
dose-limiting factor in CDDP therapy (Prestayko et al.,
1979). Chemotherapeutic agents caused host toxicity and this
is frequently the dose-limiting variable in the treatment of
cancer. One possible approach to mitigate the problem is to
conjugate the chemotherapeutic compound to antibodies
directed to the tumour associated antigens on the target
tumour cells (Gamett et al., 1983; Ohkawa et al., 1986a,b;
Tsukada et al., 1982a,b, 1984,1985). Another potentially
feasible approach to this problem would be to co-administer
an antagonistic drug(s) which would minimize host toxicity
without adversely altering tumour cell killing (Borch &
Pleasants, 1979; Bodenner et al., 1986; Naganuma et al.,
1987).
The administration of small amounts of selenium have
been shown to be an effective treatment for heavy metal
intoxication with agents such as mercury (Ganther et al.,
1972). Based on this observation Naganuma et al.
(1983,1984,1987) and Satoh et al. (1985) co-administered
selenium (CDDP: selenium, molar ratio =3.5:1) with CDDP.
They found, using a mouse plasmacytoma, that the selenium
administration depressed the toxic side effects of CDDP
without masking its antitumour activity.
In this study we have examined the effect of co-admini-
stration of selenium with CDDP on the growth of a human
yolk sac tumour which was xenografted into nude mice. Wc
have also investigated whether selenium administration
would decrease the toxicity associated with the CDDP
therapy.
Materials and methods
Animals
BALB/c female athymic nude mice (nu/nu), 5-6 weeks old
were obtained from CLEA Japan Inc., Japan. They were
kept under specific pathogen free conditions and were at
least 20g when used.
Tumour
The human yolk sac tumour (JOG-9) used in this study was
established by s.c. inoculation of a 'pure' ovarian yolk sac
tumour obtained from a 14-year old female patient (Ohkawa
et al., 1986a). The donor had not received chemotherapy.
For serial transplantation, the tumour was minced in sterile
ice-cold PBS and transplanted s.c. into nude mice. Tumours
which were in the 35th to 40th passage were used in these
studies. Human alpha-foetoprotein (AFP) was detected in
the serum of tumour bearing nude mice and correlated with
tumour burden.
Drugs
Mice bearing the JOG-9 tumour were either given single
agent or combination chemotherapy weekly via i.p. injection
(Table I). Four doses of CDDP (Bristol Myers, England)
were used; 1.3 mgkg-1 weekly (P-1.3), 2.5 mgkg1 weekly
(P-2.5), 5 mgkg- 1 weekly (P-5), and l0 mgkg 1 weekly
(P -10), respectively. Three injections were given. Combi-
nation therapy with two combination doses was studied; (1)
CDDP 5 mgkg-1, vinblastine (Sigma, USA) 1 mgkg-1 and
bleomycin (Nihon Kayaku, Japan) 2.5mgkg-1 (P - 5VB).
(2) CDDP 10mgkg-1, vinblastine 1 mgkg-1, and bleomycin
2.5mgkg-I (P -1OVB). The combination PVB regimens
were repeated for two weeks. Selenium (sodium selenite,
Sigma, USA, Se) at doses of 0.21, 0.42, 0.84 or 1.7mgkg-1
were co-administered i.p. from days 1 to 5 with CDDP with
a short interval (< I h) between the two drugs (P- 1.3SeO.21,
P-2.5ScO.42, P-5SeO.84, P-IOSel.7). One dose of Se
(1.7 mgkg- 1) was co-administered with the combination
therapy, P-1OVB. All of the drugs werc dissolved in 0.15 M
NaCl and were injected i.p. into tumour bearing mice.
Control mice were given i.p. 0.84mgkg-1 Se in the same
volume of 0.15 M NaCl as controls and there was no
observed effect on tumour growth by Se administration.
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Evaluation of chemotherapeutic effects
There were 10 mice per group and treatment was initiated
when the tumours had a volume of 3,000 to 4,000mm3.
Tumours were measured at weekly intervals with slide caliper
and the volume, mm3, was calculated by the formula
described by Houchens et al. (1978); V=W2 x L x 1/2, where
W and L are the width and length in mm. Because of the
variety of tumour sizes at the initiation of treatment, tumour
volumes were converted to values related to the initial
tumour volumes. The relative tumour volume was expressed
by the formula; Vt/Vo, where Vt is the mean tumour volume
at a given time and VO the mean volume at the initiation of
treatment. The ratio of the relative tumour volume in treated
mice over that of control mice at each treatment time was
multiplied by 100 (T/C) and calculated at each evaluation.
Blood samples were collected at regular intervals via the
tail vein. Since the serum concentration of AFP correlates
with the total tumour burden, it is possible to assess the
chemotherapeutic effect by quantitating the AFP serum
concentration. The AFP serum concentration was deter-
mined by the sandwich radioimmunoassay (Nishi & Hirai,
1973). To monitor drug toxicity the haematocrit, peripheral
white blood cell count (WBC, counted by haemocytometer),
blood urea nitrogen (BUN, mgdl-1, urea-GLDH method,
Kyowa Medex, Japan) and body weight were also measured
at the end of the experimental period (22 days after the
initiation of treatment).
Statistical analysis
Student's t test was used.
Results
The effect of co-administration of Se on lethality of CDDP
in nude mice was examined. The 50% lethal dose (LD50) of
CDDP in nude mouse was determined by single i.p. injection
at 5 doses in the toxic range and the survival results were
calculated. When the adequate doses of Se were co-admini-
stered i.p. after scaled doses of CDDP, the CDDP LD50
increases from 9.3+0.4mgkg-1 to 17.5+0.9mgkg-1 (n=10,
mean+s.d.), corresponding to a dose modification factor of
1.9.
The antitumour effect of each regimen is shown in Figure
la,b and Table I. With either single agent therapy with
CDDP or combination therapy there was a dose dependent
antitumour effect. CDDP at a minimum dose (P-1.3) did
not retard tumour growth while both P-2.5 and P-5
regimens caused a moderate to marked reduction of the
tumour volume. Complete remissions of the tumours were
achieved with 5 regimens (P-5, P-5SeO.84, P-lOSel.7,
P- 5VB, P- 1OVBSel.7) and no tumour was evident 3 weeks
after the initiation of treatment. In the single agent regimens
the combination of CDDP and Se (P-lOSel.7) was the
most efficient as there was a significant reduction in tumour
volume (T/C =3 +0.2, P<0.01), at one week after the initia-
tion of treatment. No significant differences were observed
with and without Se with any of the drugs regimens.
In PVB combination therapy the antitumour activity of
P-lOVBSel1.7 was statistically greater as there was a signifi-
cant reduction of the tumour volume (T/C =0.4+0.01,
P<0.001) over that which occurred with the P-5VB regi-
men (T/C =2.0+0.08). The dose of l0mgkg-1 CDDP when
administered alone or in combination therapy was toxic as
all mice died within 9 days post treatment. The co-admini-
stration of Se with CDDP at the dose of 10mgkg-1 alone
or in combination therapy (P-lOSel.7, P-IOVBSel.7) was
found to prevent the lethal toxicity of CDDP but the
marked antitumour activity associated with the high doses of
CDDP remained.
The serum AFP levels correlated with the tumour volumes
in all of the experimental groups (Figure 2).
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Figure 1 (a), (b) The effects of CDDP (single agent treatment in
a, combination treatment in b with and without co-admini-
stration of Se. Each 7 group of mice (n= 10) were inoculated s.c.
with tumour at -2 weeks. Starting 2 weeks later when the
tumour size reached 3,000 to 4,000mm3 (0), different groups
received weekly i.p. injections (arrows) of one of the following
regimens; (a) CDDP 1.3mgkg-1 (P-1.3, 0), CDDP
2.5mgkg-1 (P-2.5, *), CDDP 5mgkg-1 (P-5, *), CDDP
10mgkg-1 (P-10, ), CDDP 1.3mgkg-1+Se 0.21mgkg-1
(P-1.3Se 0.21, 0), CDDP 2.5mgkg-1+Se 0.42mgkg-1
(P-2.5Se 0.42, O), CDDP 5mgkg-1 +Se 0.84mgkg-1 (P-5Se
0.84, A), CDDP l0mgkg-'+Se 1.7mgkg-1(P-l0Se 1.7, El);
(b) CDDP 5mgkg-1 +vinblastine (I mgkg-1)+bleomycin
(2.5 mgkg-1) (P-5VB, A), CDDP I0mgkg-1 +vinblastine+
bleomycin (P-lOVB, *), P-lOVB+Se 1.7 mgkg - I (P-lOVBSe
1.7. O). Se was co-administered i.p. from I to 5 days (arrow
heads) with each therapeutic regimen. Control mice were given
i.p. of 0.84mgkg-1 of Se (x). Results are expressed as
mean+s.e. for each group.
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Table I Therapeutic regimens and summary of the antitumour activity
Drug (mgkg 1) T/Cd at each week
Regimen CDDP VLB BLM Se Ist 2nd 3rd
P-1.3a 1.3 - - - 64+20 76+ 18 77+21
P- 1.3SeO.21a 1.3 - - 0.21 65+ 18 74+23 75+ 9
P-2.5a 2.5 - - - 22+ 3 10+ 3 4+0.4
P -2.5SeO.42a 2.5 - - 0.42 24+ 5 8+ 2 3+0.2
p_ a 5.0 - - - 7+0.2 0.4+0.05 Sg
P-SSeO.84a 5.0 - - 0.84 4+0.3 0.2+0.1 S
P loa 10.0 - - - 2e dead' dead
P lOSel.7a 10.0 - - 1.70 3+0.08 S S
P-5VBb 5.0 1.0 2.5 - 2+0.08 S S
P-IOVBb 10.0 1.0 2.5 - dead dead dead
P-IOVBSe1.7b 10.0 1.0 2.5 1.70 0.4+0.01 S S
controlc - - - 0.84
CDDP; cis-platin, VLB; vinblastine, BLM; bleomycin, Se; selenium; aThree injec-
tions of 4 doses of CDDP (1.3, 2.5, 5.0, 10.Omgkg-1) with or -without Se (0.21, 0.42,
0.84, 1.70mgkg-1) were given i.p. weekly. Each dose of CDDP was given at day 1
and Se was co-administered from day 1 to 5; bTwo combination doses without Se and
one dose with Se were repeated for 2 weeks. Each dose of CDDP, VLB and BLM was
given at day 1 and Se was from day 1 to 5; cControl mice received 0.84mgkg-1 Se
i.p. for 5 daily injections; dT/C+s.e. were calculated by the method described in
Materials and methods for each week; eThree mice survived until 9 days after the
initiation of treatment; 'dead: death due to drug toxicity; 9S: tumour resulted in scar.
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Figure 2 Serum AFP levels in nude mice treated with test
materials. The serum AFP level was measured by radioimmuno-
assay with respect to mice treated with P- 1.3 (-0-), P-2.5
( * ), P-5( A ),P-10 ( -), P-1.3SeO.21 ( O ),
P- 2.5SeO.42 (- O ), P-SSeO.84 ( A ), P-lOSel.7 ( OI ),
P-SVB (-A-), P-OVB ( *-), P-lOVBSel.7
(--O--), and control (- x ). Poinlt nm.1ca h.al. s.d.
The effect of co-administration of Se on reduction of
CDDP-induced adverse effects is summarized in Table II.
The administration of CDDP without Se caused significant
elevation of BUN (5-12-fold) noted in treated mice. The
significant elevation of BUN was not observed when Se was
co-administered with CDDP. Mice treated with CDDP as a
single agent or in combination therapy also showed a
significant (P<0.05) decrease of peripheral WBC and hae-
matocrit while those receiving Se showed less toxicity. The
loss of body weight in the groups of mice receiving CDDP
without Se was more profound than in the groups of mice
Table II Summary of side effectsa of each regimen on human yolk
sac tumour xenografted into nude mice
Regimenb Htc WBcC Mouse weightd BUNe
P-1.3 30 2.3+0.4 26 (+15) 220
P-1.3SeO.21 45 7.8+1.6 25 (+14) 22
P-2.5 28 2.8+0.5 25 (-10) 248
P-2.5SeO.42 51 7.0+0.9 26 (-12) 25
P-5 31 2.3+0.5 17 (-29) 215
P-SSeO.84 60 6.5+0.8 20 (-20) 26
P-10 dead' - -
P-lOSel.7 51 6.0+1.6 20 (-20) 28
P-SVB 25 NT5 17 (-26) 239
P-lOVB dead
P-lOVBSe1.7 29 NT 19 (-27) 35
control 40 11.2+3 32 (+35) 21
IaToxicologic studies were performed at 22 days after the initiation
of the treatment; bDoses in each regimen are described in Table I
and Materials and methods; CHematocrit (Ht) and white blood cell
counts (WBC) are expressed as the mean % and the mean+s.d. x
10-3mm3 of each group of mice, respectively, at the 3rd week after
the initiation of treatment; dChanges in body weight (g) were
measured weekly and expressed as the mean weight at termination of
treatment (and mean % changes in each group of mice calculated
from the formula; body weight after treatment/body weight before
treatment x 100); CBUN (mgdl-1) was measured with urea-GLDH
method and is expressed as the mean of each group of mice; 'dead:
death due to drug toxicity: gNT: not tested.
receiving CDDP with Se. Although this difference was not
statistically significant, it does imply that co-therapy with Se
may help to minimize the drug associated weight loss
toxicity.
Discussion
In the present study, we evaluated the antitumour activity of
CDDP with or without co-administration of Se against a
human yolk sac tumour growing in nude mice. Our study
supports the previously published findings with mouse
tumours that the co-administration of Se with CDDP treat-
ment retains antitumour activity while decreasing host toxi-
city (Naganuma et al., 1983,1984; Satoh et al., 1985). In our
experiments we used as our experimental model a human
yolk sac tumour which was transplanted into nude mice.
CDDP administrated as a single agent or in combination
therapy demonstrated a dose dependent antitumour activity.
This activity was the same with and without additional Se.EFFECT OF SELENIUM ON CDDP ACTIVITY 41
There was, however, a marked decrease in the severe adverse
chemotherapy side effects such as nephrotoxicity, myeloid
suppression and body weight loss observed in the groups of
mice to which Se was given. As a result of a protective effect
of Se on CDDP-induced lethal toxic side effects, a 1.9-fold
increase in CDDP LD50, when compared with the CDDP
alone, was obtained. Improvement in therapeutic index may
also be obtained because the data clearly show that co-
administration of Se increases the therapeutic index of
CDDP since its antitumour activity is maintained but the
host toxicity is reduced. This phenomenon was readily
observed with the high toxic level doses of 10mgkg-1
CDDP (P-10, P-lOSel.7, P-IOVB and P-IOVBSel.7).
Mice treated with CDDP at the dose of 10mgkg-t, com-
bined with Se, revealed marked tumour regression with
minimal adverse side effects. In contrast, the groups of mice
receiving the same dose of CDDP without Se all died due to
drug toxicity within 9 days after the initiation of treatment.
Some side effects could be quantitated such as elevation of
BUN, decrease of body weight, reduction of haematocrit,
and decrease in WBC was rarely noted in mice which
received CDDP with an adequate dose of Se. We could not
accumulate any information about the potential beneficial
therapeutic effect of Se to prevent nausea and severe vomit-
ing (Bodenner et al., 1986).
Little information is available on the pharmacokinetics of
the interaction of CDDP with Se. It was recently reported
that the toxic action of CDDP was probably caused not by
the coordination structure of CDDP, which is necessary for
antitumour activity, but by the compound Pt2 + arising from
the decomposition of CDDP in vivo (Naganuma et al., 1983).
It would therefore by reasonable to speculate that Se may
interact with toxic Pt2 + derived from CDDP. This could
happen if formation of a metal-Se complex occurred in vivo.
Naganuma et al. (1987) reported that the preadministration
of bismuth, which has been used as a metallothionein
inducer, was effective in decreasing CDDP toxicity while
antitumour activity remained. In our preliminary studies, no
significant elevation of metallothionein in kidney tissues
from Se-treated mice was found (data not shown). Recently
diethyldithiocarbamate has been shown to decrease the
CDDP induced toxicity without any reduction of antitumour
activity (Bodenner et al., 1986) but the explanation is
unclear. From our data it can be concluded that co-
administration of Se with CDDP (CDDP: Se, molar ratio,
3.5:1) is associated with the beneficial effect of decreasing
CDDP mediated toxicity with concomitant-retention of anti-
tumour activity. This indirectly suggests that more effective
chemotherapeutic treatment of cancer in humans with
CDDP may be possible if the chemotherapy includes Se.
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